Efficacy of Motavizumab for the Prevention of Respiratory Syncytial Virus Disease in Healthy Native American Infants: A Phase 3 Randomised Double-blind Placebo-controlled Trial

Virus Disease ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(15)00247-9 ◽

2015 ◽

Vol 15 (12) ◽

pp. 1398-1408 ◽

Cited By ~ 98

Author(s):

Katherine L O'Brien ◽

Aruna Chandran ◽

Robert Weatherholtz ◽

Hasan S Jafri ◽

M Pamela Griffin ◽

...

Keyword(s):

Native American ◽

Virus Disease ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725888977.793559350 ◽

2019 ◽

Author(s):

Fernando Polack

Keyword(s):

Native American ◽

Virus Disease ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial

Yearbook of Pediatrics ◽

10.1016/s0084-3954(09)79553-3 ◽

2011 ◽

Vol 2011 ◽

pp. 504-506

Author(s):

J.A. Stockman

Keyword(s):

Virus Infection ◽

Respiratory Syncytial Virus Infection ◽

Inhaled Corticosteroids ◽

Controlled Trial ◽

High Dose ◽

Double Blind ◽

Double Blind Placebo ◽

1971. A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects

Open Forum Infectious Diseases ◽

10.1093/ofid/ofy210.1627 ◽

2018 ◽

Vol 5 (suppl_1) ◽

pp. S572-S572 ◽

Cited By ~ 4

Author(s):

Antonios Aliprantis ◽

Dennis Wolford ◽

Luzelena Caro ◽

Brian Maas ◽

Hua Ma ◽

...

Keyword(s):

Monoclonal Antibody ◽

Healthy Subjects ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Neutralizing Monoclonal Antibody ◽

A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease

Pediatric Research ◽

10.1203/pdr.0b013e318220a553 ◽

2011 ◽

Vol 70 (2) ◽

pp. 186-191 ◽

Cited By ~ 62

Author(s):

Timothy F Feltes ◽

Henry M Sondheimer ◽

Robert M R Tulloh ◽

Brian S Harris ◽

Kathryn M Jensen ◽

...

Keyword(s):

Congenital Heart Disease ◽

Randomized Controlled Trial ◽

Heart Disease ◽

Congenital Heart ◽

Virus Disease ◽

Controlled Trial ◽

Randomized Controlled ◽

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.37.8.1655 ◽

1993 ◽

Vol 37 (8) ◽

pp. 1655-1658 ◽

Cited By ~ 62

Author(s):

H C Meissner ◽

D R Fulton ◽

J R Groothuis ◽

R L Geggel ◽

G R Marx ◽

...

Keyword(s):

High Risk ◽

Immune Globulin ◽

Virus Disease ◽

Controlled Trial ◽

Intravenous Immune Globulin ◽

Syncytial Virus ◽

High Risk Infants

Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis

Thorax ◽

10.1136/thx.52.7.634 ◽

1997 ◽

Vol 52 (7) ◽

pp. 634-637 ◽

Cited By ~ 77

Author(s):

J. B. van Woensel ◽

T. F. Wolfs ◽

W. M. van Aalderen ◽

P. L. Brand ◽

J. L. Kimpen

Keyword(s):

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Respiratory Syncytial Virus Bronchiolitis ◽

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

Clinical Pharmacology in Drug Development ◽

10.1002/cpdd.883 ◽

2020 ◽

Author(s):

Antonios O. Aliprantis ◽

Dennis Wolford ◽

Luzelena Caro ◽

Brian M. Maas ◽

Hua Ma ◽

...

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Phase 1 ◽

Healthy Adults ◽

Double Blind ◽

Double Blind Placebo ◽

Neutralizing Monoclonal Antibody ◽

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Dexamethasone in Severe Respiratory Syncytial Virus (RSV) Infection: Effects on RSV Quantity and Clinical Outcome

The Journal of Infectious Diseases ◽

10.1086/340024 ◽

2002 ◽

Vol 185 (9) ◽

pp. 1222-1228 ◽

Cited By ~ 70

Author(s):

Steven C. Buckingham ◽

Hasan S. Jafri ◽

Andrew J. Bush ◽

Cecilia M. Carubelli ◽

Paul Sheeran ◽

...

Keyword(s):

Clinical Outcome ◽

Controlled Trial ◽

Severe Respiratory Syncytial Virus ◽

Double Blind ◽

Double Blind Placebo ◽

Rsv Infection ◽

Ribavirin in respiratory syncytial virus infection. A double blind placebo controlled trial is needed.

Archives of Disease in Childhood ◽

10.1136/adc.63.8.986 ◽

1988 ◽

Vol 63 (8) ◽

pp. 986-990 ◽

Cited By ~ 11

Author(s):

D Isaacs ◽

E R Moxon ◽

D Harvey ◽

I Kovar ◽

C R Madeley ◽

...

Keyword(s):

Virus Infection ◽

Respiratory Syncytial Virus Infection ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽